Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Rani Therapeutics Holdings, Inc. has received an average rating of "Moderate Buy" from five analysts, with one sell recommendation and four buy recommendations.
• The company's stock price increased by 52.1% to $2.50, with a 12-month low of $0.39 and a high of $2.82.
• Rani Therapeutics reported an earnings per share (EPS) of ($0.18), which surpassed the consensus estimate of ($0.19) by $0.01.

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $8.00.

RANI has been the subject of several research reports. Maxim Group upped their target price on Rani Therapeutics from $5.00 to $10.00 and gave the stock a "buy" rating in a research note on Monday. Wall Street Zen raised Rani Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Rani Therapeutics in a research note on Wednesday, October 8th.

Rani Therapeutics Trading Up 52.1%

Shares of NASDAQ RANI traded up $0.86 during midday trading on Monday, hitting $2.50. 135,122,303 shares of the company's stock were exchanged, compared to its average volume of 4,109,518. Rani Therapeutics has a 12-month low of $0.39 and a 12-month high of $2.82. The company has a market cap of $179.32 million, a price-to-earnings ratio of -2.85 and a beta of -0.02. The business's fifty day moving average price is $0.53 and its two-hundred day moving average price is $0.65.

Rani Therapeutics (NASDAQ:RANI - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.01. Equities analysts expect that Rani Therapeutics will post -1.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in RANI. Well Done LLC purchased a new position in shares of Rani Therapeutics in the second quarter worth $27,000. Janney Montgomery Scott LLC increased its stake in shares of Rani Therapeutics by 102.9% in the second quarter. Janney Montgomery Scott LLC now owns 55,200 shares of the company's stock worth $28,000 after buying an additional 28,000 shares during the period. King Luther Capital Management Corp increased its stake in shares of Rani Therapeutics by 75.8% in the first quarter. King Luther Capital Management Corp now owns 58,000 shares of the company's stock worth $73,000 after buying an additional 25,000 shares during the period. CWA Asset Management Group LLC purchased a new position in shares of Rani Therapeutics in the first quarter worth $105,000. Finally, Kestra Private Wealth Services LLC raised its holdings in shares of Rani Therapeutics by 16.3% during the first quarter. Kestra Private Wealth Services LLC now owns 139,156 shares of the company's stock valued at $175,000 after acquiring an additional 19,536 shares in the last quarter. 30.19% of the stock is owned by hedge funds and other institutional investors.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.